Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter, Corey A; Degesys, Aiste; Oronsky, Bryan; Scicinski, Jan; Caroen, Scott Z; Oronsky, Arnold L; Reid, Tony; Cabrales, Pedro; Roswarski, Joe

Carter, Corey A; Degesys, Aiste; Oronsky, Bryan; Scicinski, Jan; Caroen, Scott Z; Oronsky, Arnold L; Reid, Tony; Cabrales, Pedro; Roswarski, Joe.

Afiliación

Carter CA; Walter Reed National Military Medical Center, Bethesda, Md., USA.
Degesys A; Walter Reed National Military Medical Center, Bethesda, Md., USA.
Oronsky B; EpicentRx, Inc., Mountain View, Calif., USA.
Scicinski J; EpicentRx, Inc., Mountain View, Calif., USA.
Caroen SZ; EpicentRx, Inc., Mountain View, Calif., USA.
Oronsky AL; InterWest Partners, Menlo Park, Calif., USA.
Reid T; Moores Cancer Center, University of California, La Jolla, Calif., USA.
Cabrales P; Department of Bioengineering, University of California, La Jolla, Calif., USA.
Roswarski J; Walter Reed National Military Medical Center, Bethesda, Md., USA.

Case Rep Oncol ; 8(3): 461-5, 2015.

Article en En | MEDLINE | ID: mdl-26600780

Palabras clave

Carcinoid syndrome; Epigenetics; Neuroendocrine tumor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Case Rep Oncol Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google